Abstract: A method of treating hypovolemic shock and related shock syndromes by the administration of substantially non-anticoagulant heparinoids without the hemorrhaging problems generally associated with heparin; such syndromes include degradation of the microvascular structure, immune and gastrointestinal tract dysfunction, and multiple organ failure.
Type:
Grant
Filed:
May 31, 1994
Date of Patent:
December 10, 1996
Assignees:
Michigan State University, Glycomed Incorporated
Abstract: Disclosed are novel Lewis.sup.x and Lewis.sup.a analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.
Type:
Grant
Filed:
November 4, 1994
Date of Patent:
December 3, 1996
Assignee:
Alberta Research Council
Inventors:
Robert M. Ippolito, Wasimul Haque, Cong Jiang, H. Rizk Hanna, Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem, Richard H. Smith
Abstract: A pharmaceutical composition comprising dermatan sulphate, together with a low molecular weight heparin, free or fixed combination, is useful as a antithrombolytic agent with a low risk of bleeding complications.
Abstract: The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention.
Abstract: Fermentation product A83543, comprising major components A83543A and A83543D and minor components A83543B, A83543C, A83543E, A83543F, A83543G, A83543H and A83543J, is produced by a newly described species, Saccharopolyspora spinosa. The A83543 components and their acid-addition salts (A83543 compounds) are useful as insecticides, particularly against Lepidoptera and Diptera species. Insecticidal, miticidal or ectoparasiticidal combinations, compositions and methods are provided.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
November 5, 1996
Assignee:
DowElanco
Inventors:
LaVerne D. Boeck, Hang Chio, Tom E. Eaton, Otis W. Godfrey, Jr., Karl H. Michel, Walter M. Nakatsukasa, Raymond C. Yao
Abstract: Synthetic compounds which are useful for suppressing an immune response are disclosed. The synthetic compounds have the formula ##STR1## wherein A is a carbohydrate moiety which corresponds to the carbohydrate moiety of a naturally occurring ganglioside, n is 5 to 20 and m is to 20. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing the compounds as shown above.
Type:
Grant
Filed:
September 14, 1994
Date of Patent:
October 22, 1996
Assignee:
The Regents of The University of California
Abstract: There is provided novel sulfated p-glycolipid compounds of the formula ##STR1## wherein R is an acyl residue of a fatty acid;R.sup.1 is --(CH.dbd.CH).sub.m --(CH.sub.2).sub.n --CH.sub.3 ;R.sup.2, R.sup.3, R.sup.4 and R.sup.6 each are independently --SO.sub.3 H, hydrogen, unsubstituted or substituted alkanoyl, arylalkyl or arylcarbonyl wherein said substituent is selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, hydroxy and C.sub.1-4 alkoxy; or R.sub.4 and R.sub.6, taken together are isopropylidene; provided at least two of R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are --SO.sub.3 H;R.sup.5 is hydrogen, unsubstituted or substituted alkanoyl, arylalkyl or arylcarbonyl wherein said substituent is selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, hydroxy and C.sub.
Type:
Grant
Filed:
February 12, 1996
Date of Patent:
October 15, 1996
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jacques Banville, Alain Martel, Alejandro A. Aruffo
Abstract: Glycosylated prodrugs, a preparation method therefor, and their use with tumor-specific immunoenzymatic conjugates for the treatment of cancer, are described. These anthracycline prodrugs have formula (I).
Abstract: The present invention relates to bivalent sialyl Lewis X saccharide compounds that inhibit cellular binding to a selectin receptor. Pharmaceutical compositions containing a compound of Formula I, and processes for making and using the same are disclosed. A contemplated bivalent sialyl Lewis X saccharide compound has a structure that corresponds to Formula I, below, ##STR1## wherein R is a directly linked divalent monosaccharide unit; Y is selected from the group consisting of C(O), SO.sub.2, HNC(O), OC(O) and SC(O);R.sup.2 is selected from the group consisting of a C.sub.1 -C.sub.6 hydrocarbyl, an aryl, a substituted aryl and a phenyl C.sub.1 -C.sub.3 alkylene group, wherein an aryl group has one six-membered aromatic ring or two fused six-membered aromatic rings, which ring or rings are hydrocarbyl, monoazahydrocarbyl, or diazahydrocarbyl rings, and a substituted aryl group is a before-mentioned aryl group having a substituent selected from the group consisting of halo, trifluoromethyl, nitro, C.sub.1 -C.
Abstract: A highly pure fraction of hyaluronic acid is disclosed which is non-inflammatory and avoids post-operative complications in ocular surgery. Also disclosed is a process for the preparation of hyaluronic acid characterized by converting hyaluronic acid into a corresponding quaternary ammonium salt and, following purification procedures, reconverting the quaternary ammonium salt into a sodium salt of hyaluronic acid.
Abstract: This invention relates to an improved process for the synthesis of 4-alkoxy-N-acetylneuraminic acids. According to the process of the invention, N-acetylneuraminic acid is first alkylated at C-1 and C-2 and then the vicinal hydroxyl groups at C-8 and C-9 are protected through the formation of a ketal. The resulting protected alkyl ester alkyl ketoside is then alkylated at the C-4 position whereby the hydrogen of the C-4 hydroxyl group is replaced with an alkyl group to form an alkoxy group. Deprotection is accomplished through the removal of the ketal group at C-8 and C-9 and removal of the alkyl groups at C-1 and C-2, thereby producing the 4-alkoxy-N-acetylneuraminic acid.
Type:
Grant
Filed:
August 5, 1994
Date of Patent:
September 17, 1996
Assignee:
Oklahoma Medical Research Foundation
Inventors:
Avraham Liav, Ragen F. Hardgrave, Sheri Blystone, Gregory A. Turner
Abstract: The invention relates to N,O-sulphated heparosans consisting of chains or of a mixture of chains of molecular mass between 1500 and 15,000 Da, characterized by a repeated disaccharide structure of formula I: ##STR1## in which: E represents an acetyl group in 0 to 80% of the disaccharide units of the said N,O-sulphated heparosan, and a sulphate group and possibly a hydrogen atom in the remaining disaccharide units,G represents a hydrogen atom and a sulphate group, and the pharmaceutically acceptable salts of thesaid N,O-sulphated heparosans. The heparosans are useful as anticoagulants.
Type:
Grant
Filed:
February 15, 1995
Date of Patent:
August 27, 1996
Assignee:
Sanofi
Inventors:
Jean Claude Lormeau, Bruno Chevallier, Marc L. V. Salom e, Guy E. M. Tenaille d'Estais
Abstract: A natural dermatan sulphate with antithrombinic activity in excess of 220 U/mg which comprises an oligosaccharide sequence with a high degree of sulfation, having formula (III) ##STR1## in which: n=integers 1 or 2; R.sub.4 =SO.sub.3, or H; R.sub.6 =H, or SO.sub.3 ; G=glucuronic acid: I--non-sulfated uronic acid, preferably glucuronic acid, is extracted from organs, and subsequently purified in mild operating conditions, at pH 5-7, isolation and fractionation being carried out with macroreticular ion exchange resins, having a particle size of less than 10 .mu..
Abstract: Disclosed are a novel desiccant containing a non-reducing anhydrous trehalose as an effective ingredient; a dehydration of hydrous matters, e.g. food products, pharmaceuticals and cosmetics, therewith; and dehydrated products obtained by the dehydration. Such hydrous matters are dehydrated without causing alteration or deterioration by incorporating anhydrous trehalose into the hydrous matters to convert the anhydrous trehalose into hydrous crystalline trehalose. The anhydrous trehalose are anhydrous crystalline trehalose and hydrous amorphous trehalose.
Abstract: A method of anti-metastatic and/or anti-inflammatory treatment of an animal or human patient comprises administration to the patient of an effective amount of at least one sulphated polysaccharide which blocks or inhibits endoglycosidase, particularly heparanase, activity. Suitable sulphated polysaccharides include heparin and modified heparin, fucoidan, pentosan sulphate, dextran sulphate and carrageenan lambda.
Abstract: This invention provides a method of altering the water content of a hydrogel comprising treatment of said hydrogel with a liquid dehydrating composition. There is further provided a method of altering the water content of a hydrogel-containing medical device. The medical devices of the present invention comprise a hydrogel having a water level ex vivo lower than the thermodynamic equilibrium water level when in vivo. These medical devices comprise a hydrogel contacted with a liquid dehydrating agent, wherein said medical device has a lower water level ex vivo than the thermodynamic equilibrium water level when the medical device is in vivo.
Abstract: A material compatible with blood obtained by heparinizing a polymer having quarternary ammonium groups with an alkali metal salt or an alkaline earth metal salt of heparin or the analog by ion exchange is provided. The equivalent ratio (M/S) of alkali metal atoms or alkaline earth metal atoms (M) in the heparin or the analog bonded to the polymer to sulfur atoms (S) in heparin or the analog bonded to the polymer is 0.4 or less.
Abstract: A composition for coating medical blood contacting surfaces comprises a mixture of an anticoagulant and a defoaming agent. The coating composition is applied by either dipping the device into a solution containing the mixture or by spraying the mixture onto the surface. Alternatively, the surface can be sequentially dip coated and/or sprayed with the individual components. In a preferred embodiment, the anticoagulant is a quaternary ammonium complex of heparin, preferably stearyldimethylbenzyl ammonium heparin, and the antifoaming agent is a mixture of polydimethylsiloxane and silicon dioxide.
Abstract: Process for the preparation of complexes of iodine with chitosan or derivatives thereof, and the iodinated compounds thus obtainable. Said compounds take form of powders, which may contain over 60% of iodine in its elementary form. In a dry state the iodine bound to the chitosan or derivatives thereof does not sublimate. If the percentage content of iodine does not exceed 50 % (by weight), said powders can be dissolved in aqueous solvents of an acid type, such as, for example, diluted acetic acid or glutamic acid. Said solutions are compatible with addition of surfactants, preferably of a non-ionic type, which improve the solubility of the chitosan-iodine complex. Solutions with identical characteristics can, alternatively, be prepared by solubilizing, heating if necessary the iodine in a suitable surfactant, preferably non-ionic, and adding this solution under rapid stirring to the chitosan derivatives thereof, dissolved in water, optionally in the presence of acids or salts.
Type:
Grant
Filed:
January 3, 1995
Date of Patent:
July 23, 1996
Assignees:
Development Biotechnological Processes S.N.C Di Pelliccia Maria Teresa, IMS-International Medical Service SRL
Inventors:
Alfredo De Rosa, Armando Rossi, Pietro Affaitati
Abstract: This invention relates to 12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione derivatives represented by the following general formula, pharmaceutically acceptable salts thereof, a method for preparation thereof and a use thereof: ##STR1## [wherein R.sup.1 denotes a monosaccharide group having 5 to 7 carbon atoms, and the hydroxyl groups of this monosaccharide group can be replaced by the same or different 1 to 3 groups selected from the group consisting of a hydrogen atom, lower alkyl group, lower alkylcarbonyloxy group and lower alkoxy group.